CYP2C19*2 & *3 Detection Kit (RUO)

Drug & Gene Information:

 

Relating to Drug: Clopidogrel (Brand name: Plavix)

Clodpgrel, an antiplatelet agents is indicated for the reduction of thrombotic events as follows: Recent MI, Recent Stroke or Established Peripheral Arterial Disease. For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.


CYP2C19*2 & *3 Detection Kit (RUO)

CYP2C19*2 & *3 Detection Kit (RUO) -  |

CYP2C19*2 & *3 Detection Kit (RUO)

  • Pharmacokinetic and antiplatelet tests of the active metabolite of Clopidogrel show that the drug levels and antiplatelet effects differ depending on the genotype of the CYP2C19 enzyme.
  • The following represent the different alleles of CYP2C19 that make up a patient's genotype:
    1. The CYP2C19*1 allele has fully functional metabolism of Clopidogrel
    2. The CYP2C19*2 and *3 alleles have no functional metabolism of Clopidogrel. These two alleles account for most of the reduced function alleles in patients of Caucasian (85%) and Asian (99%) descent classified as poor metabolizers.
  • In March 2010, the US FDA put a black box warning on Plavix to make patients and healthcare providers aware that CYP2C19 poor metabolizers, representing up to 14% of patients, are at high risk of treatment failure and that testing is available.
  • Pharmigene, Inc. conducted in development CYP2C19*2 & *3 Detection Kit, and sequencing methods for product validation.